Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer
Shots:
- The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in 763 patients for the 1L treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
- The P-III KEYNOTE-062 results: as monothx. met its 1EPs- noninferior to CT; as a combination therapy- no superiority for OS & PFS compare to CT as monothx.; no new safety signals observed; presented at ASCO on Jun 02- 2019
- Keytruda (pembrolizumab- IV- 100mg) is a mAb blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 and activating the T lymphocytes and is evaluated in 950+ trials for multiple indications
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com